| Selzentry (maraviroc) / ViiV Healthcare |
ACTRN12611000816954: A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART): MARCH study |
|
|
| Recruiting | 4 | 560 | | | University of New South Wales, Kirby Institute, Pfizer Inc., a Delaware Corporation | HIV | | | | |
2010-023625-38: Trial to investigating the effect of Maraviroc on movement of microbes across the gut wall in HIV-1 infected individuals who are receiving antiretroviral therapy |
|
|
| Ongoing | 4 | 10 | Europe | Film-coated tablet, Celsentri film-coated tablets | Guy's and St Thomas' NHS Foundation Trust, ViiV Healthcare UK Ltd. | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2013-004809-24: The role of Home packs of HIV PEPSE in High Risk Individuals |
|
|
| Ongoing | 4 | 140 | Europe | Film-coated tablet, Celsentri (Trial Arm A), Truvada (Trial Arm A), Celsentri (Trial Arm B), Truvada (Trial Arm B) | Guy's & St. Thomas' NHS Foundation Trust, Viiv Healthcare UK Ltd, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002134-31: Maraviroc and cardiovascular risk in HIV+ patients. Maraviroc e rischio cardiovascolare in pazienti HIV+. |
|
|
| Ongoing | 4 | 40 | Europe | NA, NA, Film-coated tablet, Celsentri | Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario, Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario | HIV-1 infection. Infezione da HIV-1., HIV-1 HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2008-002978-35: Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants |
|
|
| Ongoing | 4 | 20 | Europe | MARAVIROC, | AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | First line therapy of HIV-1-infected patients. | | | | |
2008-003635-20: Maraviroc Immune Recovery Study (MIRS):A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery |
|
|
| Ongoing | 4 | 130 | Europe | Celsentry, Celsentry | Universitair Medisch Centrum Utrecht | HIV-1 infection | | | | |
2008-006286-80: Evaluación de los niveles farmacológicos de Maraviroc en Líquido Cefalorraquídeo (LCR) y semen en sujetos infectados por el VIH. |
|
|
| Ongoing | 4 | 12 | Europe | Celsentri, Celsentri | Daniel Podzamczer Palter | Infección por VIH | | | | |
2009-014694-40: A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy |
|
|
| Ongoing | 4 | 12 | Europe | | | HIV | | | | |
2010-022202-41: ESTUDIO PILOTO DEL CAMBIO EN LA ACTIVIDADANTIRRETROVIRAL EN SISTEMA NERVIOSO CENTRAL TRAS LA SUSTITUCIÓN DE TDF/FTC/EFV POR ABC/3TC/MVC |
|
|
| Ongoing | 4 | 15 | Europe | CELSENTRI 150 mg comprimidos recubiertos con película, ATRIPLA 600 mg/245 mg comprimidos recubiertos con película, KIVEXA 600 mg/300 mg comprimidos recubiertos con película, CELSENTRI 150 mg comprimidos recubiertos con película, ATRIPLA 600 mg/245 mg comprimidos recubiertos con película, KIVEXA 600 mg/300 mg comprimidos recubiertos con película | Daniel Podzamczer | Virus de imunodeficiencia humana-1 | | | | |
2010-023192-26: EFFECT OF SWITCHING FROM NRTIS TO MARAVIROC ON NRTI-ASSOCIATED MITCHONDRIAL TOXICITY AND IMMUNE ACTIVATION Auswirkung des Wechsels von NRTIs zu Maraviroc auf NRTI-assoziierte mitochondriale Toxizität und Immunaktivierung |
|
|
| Ongoing | 4 | 80 | Europe | Celcentri, Celcentri, Celcentri | mib Dienstleistungsgesellschaft mbH, ViiV Healthcare GmbH | Increases in inflammatory biomarkers have been associated with various non-AIDS complications such as cardiovascular events. Maraviroc has no known toxic effects on mitochondria and has been shown to reduce immune activation / inflammation in treatment intensification settings. The purpose of this study is to investigate if switching from NRTIs to Maraviroc results in reversal of NRTI-associated mitochondrial toxicity and decreases in markers of immune activation and inflammation. | | | | |
2011-003447-21: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis |
|
|
| Ongoing | 4 | 280 | Europe | Maraviroc, Celsentri, Celsentri | Camden Provider Services, Pfizer | Prophylaxis and prevention of HIV Infection. | | | | |
2012-000649-11: SSAT046 Addition of Maraviroc to monotherapy Darunavir/Ritonavir study |
|
|
| Ongoing | 4 | 30 | Europe | Darunavir, Ritonavir, Maraviroc, Prezista, Norvir, Celsentri, Prezista, Norvir, Celsentri | St Stephen\'s Aids Trust, St Stephen\'s AIDS Trust, Pfizer Inc | HIV | | | | |
2012-003778-16: The dose and genital tract concentration of Maraviroc needed for protection from HIV infection |
|
|
| Ongoing | 4 | 54 | Europe | Celsentri, Celsentri | Guy\'s & St. Thomas\' NHS Foundation Trust, Pfizer Inc | HIV | | | | |
| Not yet recruiting | 4 | 186 | NA | Placebo for MVC, Maraviroc, MVC, Placebo for DTG, Dolutegravir, DTG | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 06/17 | 06/18 | | |
2017-004141-24: A study in which people who have HIV and fatty liver disease, who do not drink excessive alcohol, are either asked to take the drug maraviroc on top of their normal anti-HIV medicines or to take their normal anti-HIV medicines alone |
|
|
| Ongoing | 4 | 60 | Europe | Celsentri, Film-coated tablet, Celsentri | Brighton and Sussex University Hospitals NHS Trus | Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection, A disease of too much fat laid down in the liver in people who have HIV and do not drink over the recommended limit of alcohol, Diseases [C] - Digestive System Diseases [C06] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
